Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

por Facon, Thierry, Moreau, Philippe, Martin, Thomas G., Spicka, Ivan, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaëlle, Schwab, Sandrine, Martinez, Gracia
Publicado 2022

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

por Capra, Marcelo, Martin, Thomas, Moreau, Philippe, Baker, Ross, Pour, Ludek, Min, Chang-Ki, Leleu, Xavier, Mohty, Mohamad, Segura, Marta Reinoso, Turgut, Mehmet, LeBlanc, Richard, Risse, Marie-Laure, Malinge, Laure, Schwab, Sandrine, Dimopoulos, Meletios
Publicado 2021

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previous...

por Trnĕný, Marek, Verhoef, Gregor, Dyer, Martin JS, Ben Yehuda, Dina, Patti, Caterina, Canales, Miguel, Lopez, Andrés, Awan, Farrukh T, Montgomery, Paul G, Janikova, Andrea, Barbui, Anna M, Sulek, Kazimierz, Terol, Maria J, Radford, John, Guidetti, Anna, Di Nicola, Massimo, Siraudin, Laure, Hatteville, Laurence, Schwab, Sandrine, Oprea, Corina, Gianni, Alessandro M
Publicado 2018